论文部分内容阅读
目的通过检测子宫颈癌及癌前病变患者血清及组织中VEGF-C的表达水平,进一步分析VEGF-C与宫颈癌淋巴转移机制相关性及临床意义,为临床宫颈癌的早期诊断和淋巴转移的发现与治疗提供新的依据。方法选择宁波大学医学院附属医院2012年1月-2013年12月收治的宫颈上皮内瘤变Ⅲ级患者46例为对照组,宫颈癌患者86例为观察组,同期正常宫颈人群50例为正常组,观察各组患者组织、血液VEGF-C水平,并观察不同分期、肿瘤类型、分化程度、淋巴结转移及治疗前后VEGF-C水平。结果观察组血清VEGF-C为(82.79±5.38)ng/ml,高于对照组[(51.22±3.07)ng/ml]和正常组[(16.05±3.19)ng/ml],对照组高于正常组(P<0.05)。治疗后观察组和对照组血清VEGF-C分别为(60.34±6.13)ng/ml和(32.45±4.42)ng/ml,均低于治疗前(P<0.05)。观察组组织VEGF-C阳性率为84.88%(73/86),高于对照组52.17%(24/46)和正常组6.00%(3/50),对照组高于正常组(P<0.05)。治疗后观察组和对照组组织VEGF-C阳性率分别为58.14%(50/86)和23.91%(11/86),均低于治疗前(P<0.05)。治疗后观察组血清和组织VEGF-C水平均高于对照组(P<0.05)。Ⅲ+Ⅳ期、中低分化及淋巴转移卵宫颈癌血清和组织VEGF-C分别为(98.27±6.13)ng/ml和91.49%(43/47),(97.36±6.05)ng/ml和94.92%(56/59)、(99.70±6.27)ng/ml和94.74%(36/48),均高于Ⅰ+Ⅱ级、高分化及未淋巴转移患者(P<0.05)。结论 VEGF-C在子宫颈癌患者中呈现较强表达,并随着肿瘤恶化程度的增加而上升,VEGF-C的水平与宫颈癌淋巴转移呈正相关。
Objective To detect the expression of VEGF-C in the serum and tissues of patients with cervical cancer and precancerous lesions and to further analyze the correlation between VEGF-C and lymph node metastasis of cervical cancer and its clinical significance. To provide a basis for early diagnosis and lymphatic metastasis of cervical cancer Discovery and treatment provide a new basis. Methods 46 cases of grade Ⅲ cervical intraepithelial neoplasia (NSCLC) from January 2012 to December 2013 in Affiliated Hospital of Medical College of Ningbo University were selected as control group, 86 cases of cervical cancer were observed group, and 50 cases of normal cervical crowd in the same period were normal The levels of VEGF-C in the tissues and blood of each group were observed. The levels of VEGF-C in different stages, tumor types, differentiation degree, lymph node metastasis and before and after treatment were observed. Results The serum levels of VEGF-C in the observation group were (82.79 ± 5.38) ng / ml higher than those in the control group [(51.22 ± 3.07) ng / ml and 16.05 ± 3.19 ng / ml, respectively) Group (P <0.05). After treatment, the serum levels of VEGF-C in the observation group and the control group were (60.34 ± 6.13) ng / ml and (32.45 ± 4.42) ng / ml, respectively, lower than those before treatment (P <0.05). The positive rate of VEGF-C in observation group was 84.88% (73/86), which was higher than that in control group (52.17%, 24/46) and normal group (6.00%, 3/50) . The positive rates of VEGF-C in observation group and control group after treatment were 58.14% (50/86) and 23.91% (11/86), respectively, which were lower than those before treatment (P <0.05). After treatment, the levels of VEGF-C in serum and tissue in observation group were higher than those in control group (P <0.05). The levels of VEGF-C in serum of patients with moderately differentiated and lymph node metastasis of stage Ⅲ + Ⅳ were (98.27 ± 6.13) ng / ml and 91.49% (43/47), (97.36 ± 6.05) ng / ml and 94.92% (56/59), (99.70 ± 6.27) ng / ml and 94.74% (36/48), respectively, which were higher than those in patients with grade Ⅰ + Ⅱ, well-differentiated and without lymphatic metastasis (P <0.05). Conclusions VEGF-C is strongly expressed in cervical cancer patients and increases with the degree of tumor progression. The level of VEGF-C is positively correlated with lymph node metastasis of cervical cancer.